Trend-Following Backtester · Guide · backtest 한국어

equity · KR

대웅제약 backtest

10 trend-following strategies were compared on the full daily history of 대웅제약. 1 beat buy-and-hold CAGR; Supertrend ranks first by Sharpe, matching the main backtester.

Data 2005-09-29 ~ 2026-07-31daily bars 5,147 (20.8 years)Costs 0.5%Venue XKRXMonthly snapshot 2026-07-31

Results by strategy

1 of 10 beat buy and hold (CAGR 7.0%, drawdown -78.5%).

Sharpe leader (same as main): Supertrend — CAGR 8.3%, MDD -65.4%, Sharpe 0.41, 52% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
Supertrend
period=18, mult=4.7
8.3%-65.4%0.410.135.3x6452%
Donchian 채널 돌파
entryN=18, exitN=42
6.4%-76.5%0.350.083.6x8165%
Parabolic SAR
step=0.01, maxStep=0.26
5.8%-67.3%0.340.093.2x26150%
SMA 크로스오버
fast=21, slow=118
5.2%-69.0%0.320.082.9x5450%
EMA 크로스오버
fast=27, slow=60
5.0%-73.1%0.310.072.8x7250%
ADX / DI 방향성
period=31, threshold=21
4.0%-56.6%0.280.072.3x6018%
MACD
fast=18, slow=56, signal=13
3.6%-77.9%0.270.052.1x23152%
볼린저 밴드 돌파
n=46, k=3.2
3.5%-55.0%0.270.062.1x3012%
Keltner 채널 돌파
emaPeriod=59, atrPeriod=29, mult=2
2.8%-76.7%0.240.041.8x9434%
ROC 모멘텀
n=66, threshold=-0.04
-0.6%-87.5%0.16-0.010.9x25859%
Buy and hold7.0%-78.5%0.380.094.1x1100%
1x 10x 2006 2009 2012 2015 2018 2021 2024 SupertrendBuy and hold
Supertrend: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -20% -39% -59% -79% 2006 2009 2012 2015 2018 2021 2024 Buy and holdSupertrend
Supertrend maximum drawdown -65.4% (2009-08-03 → 2012-07-26), recovered after 1,351 days.

Rules of the top strategy

Trades the direction of a volatility-based trend line that trails below/above price.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupAll asset reports

Read next